CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Regeneron Pharmaceuticals, Inc. - REGN CFD

    822.86
    2.09%
    1.66
    Low: 808.95
    High: 828.04
    Market Trading Hours* (UTC) Opens on Friday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 1.66
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Regeneron Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 806.03
    Open* 808.95
    1-Year Change* 9.93%
    Day's Range* 808.95 - 828.04
    52 wk Range 668.00-853.97
    Average Volume (10 days) 553.82K
    Average Volume (3 months) 9.29M
    Market Cap 87.03B
    P/E Ratio 22.79
    Shares Outstanding 108.95M
    Revenue 13.10B
    EPS 35.05
    Dividend (Yield %) N/A
    Beta 0.12
    Next Earnings Date Feb 1, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 30, 2023 822.86 13.91 1.72% 808.95 828.66 808.95
    Nov 29, 2023 806.03 12.95 1.63% 793.08 813.95 793.08
    Nov 28, 2023 800.90 13.34 1.69% 787.56 801.28 787.56
    Nov 27, 2023 797.64 -4.80 -0.60% 802.44 803.69 791.35
    Nov 24, 2023 797.31 0.50 0.06% 796.81 801.80 793.60
    Nov 22, 2023 799.26 0.35 0.04% 798.91 805.92 796.88
    Nov 21, 2023 798.42 -2.01 -0.25% 800.43 800.62 791.45
    Nov 20, 2023 801.17 9.39 1.19% 791.78 805.11 791.78
    Nov 17, 2023 802.09 3.01 0.38% 799.08 807.49 795.26
    Nov 16, 2023 796.05 -0.30 -0.04% 796.35 800.65 784.95
    Nov 15, 2023 791.89 1.89 0.24% 790.00 798.14 784.95
    Nov 14, 2023 793.25 -7.87 -0.98% 801.12 805.12 791.27
    Nov 13, 2023 796.25 7.27 0.92% 788.98 801.90 784.14
    Nov 10, 2023 798.29 -4.91 -0.61% 803.20 804.40 783.44
    Nov 9, 2023 800.21 -14.80 -1.82% 815.01 815.01 794.26
    Nov 8, 2023 821.64 -2.58 -0.31% 824.22 829.65 811.79
    Nov 7, 2023 830.58 -1.42 -0.17% 832.00 832.60 821.67
    Nov 6, 2023 832.25 21.11 2.60% 811.14 839.90 811.14
    Nov 3, 2023 816.27 -16.89 -2.03% 833.16 833.85 809.44
    Nov 2, 2023 816.26 27.65 3.51% 788.61 830.18 780.77

    Regeneron Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Thursday, February 1, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Regeneron Pharmaceuticals Inc Earnings Release
    Q4 2023 Regeneron Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 12172.9 16071.7 8497.1 7863.4 6710.8
    Revenue 12172.9 16071.7 8497.1 7863.4 6710.8
    Cost of Revenue, Total 1560.4 2437.5 1119.9 782.2 434.1
    Gross Profit 10612.5 13634.2 7377.2 7081.2 6276.7
    Total Operating Expense 7434 7124.9 4920.5 5653.6 4176.4
    Selling/General/Admin. Expenses, Total 2115.9 1824.9 1346 1834.8 1556.2
    Research & Development 3592.5 2908.1 2735 3036.6 2186.1
    Operating Income 4738.9 8946.8 3576.6 2209.8 2534.4
    Interest Income (Expense), Net Non-Operating -19.6 328.8 139.1 88.1 13.7
    Other, Net 139.5 50.2 94.7 131.2 5.4
    Net Income Before Taxes 4858.8 9325.8 3810.4 2429.1 2553.5
    Net Income After Taxes 4338.4 8075.3 3513.2 2115.8 2376.4
    Net Income Before Extra. Items 4338.4 8075.3 3513.2 2115.8 2376.4
    Net Income 4338.4 8075.3 3513.2 2115.8 2444.4
    Income Available to Common Excl. Extra. Items 4338.4 8075.3 3513.2 2115.8 2376.4
    Income Available to Common Incl. Extra. Items 4338.4 8075.3 3513.2 2115.8 2444.4
    Dilution Adjustment
    Diluted Net Income 4338.4 8075.3 3513.2 2115.8 2444.4
    Diluted Weighted Average Shares 113.5 112.2 115.1 114.6 114.8
    Diluted EPS Excluding Extraordinary Items 38.2238 71.9724 30.523 18.4625 20.7003
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS 40.4714 71.9724 30.523 18.4625 20.7003
    Total Extraordinary Items 68
    Other Operating Expenses, Total -89.9 -45.6 -280.4
    Unusual Expense (Income) 255.1
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 3158.1 3162.1 3414.4 2936.2 2857.2
    Revenue 3158.1 3162.1 3414.4 2936.2 2857.2
    Cost of Revenue, Total 404.9 457.5 540.6 317.8 297.1
    Gross Profit 2753.2 2704.6 2873.8 2618.4 2560.1
    Total Operating Expense 2141.6 2215.4 2267.6 1712.5 1747.3
    Selling/General/Admin. Expenses, Total 652 601.1 660.5 529.1 476.3
    Research & Development 1085.3 1101.2 1043.1 911.3 794.3
    Other Operating Expenses, Total -0.6 -0.5 -6.6 -45.7 -17.4
    Operating Income 1016.5 946.7 1146.8 1223.7 1109.9
    Interest Income (Expense), Net Non-Operating 68.5 -87.5 143 239 -176.8
    Other, Net -2.1 -1.2 34.9 47.1 30.1
    Net Income Before Taxes 1082.9 858 1324.7 1509.8 963.2
    Net Income After Taxes 968.4 817.8 1197.1 1315.7 852.1
    Net Income Before Extra. Items 968.4 817.8 1197.1 1315.7 852.1
    Net Income 968.4 817.8 1197.1 1315.7 852.1
    Income Available to Common Excl. Extra. Items 968.4 817.8 1197.1 1315.7 852.1
    Income Available to Common Incl. Extra. Items 968.4 817.8 1197.1 1315.7 852.1
    Diluted Net Income 968.4 817.8 1197.1 1315.7 852.1
    Diluted Weighted Average Shares 113.9 114 114.1 112.8 114
    Diluted EPS Excluding Extraordinary Items 8.50219 7.17368 10.4917 11.664 7.47456
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 8.50219 7.66579 10.7546 11.664 9.20263
    Unusual Expense (Income) 0 56.1 30 0 197
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 15884.1 14014.9 9779.1 7689.1 6447.6
    Cash and Short Term Investments 7742.3 5694.7 3587 3214.3 2809.9
    Cash & Equivalents 3105.9 2885.6 2193.7 1617.8 1467.7
    Short Term Investments 4636.4 2809.1 1393.3 1596.5 1342.2
    Total Receivables, Net 5328.7 6036.5 4114.7 2672.2 2243.2
    Accounts Receivable - Trade, Net 5328.7 6036.5 4114.7 2672.2 2243.2
    Total Inventory 2401.9 1951.3 1916.6 1415.5 1151.2
    Prepaid Expenses 411.2 332.4 160.8 387.1 243.3
    Other Current Assets, Total
    Total Assets 29214.5 25434.8 17163.3 14805.2 11734.5
    Property/Plant/Equipment, Total - Net 3763 3482.2 3221.6 2890.4 2575.8
    Property/Plant/Equipment, Total - Gross 5432.2 4880.3 4352.7 3812.8 3304.5
    Accumulated Depreciation, Total -1669.2 -1398.1 -1131.1 -922.4 -728.7
    Long Term Investments 6640.1 6878 3194.8 3312.4 1800.5
    Other Long Term Assets, Total 2011.8 1059.7 967.8 913.3 910.6
    Total Current Liabilities 3141.3 3932.5 2697.4 2096.6 1442.8
    Accounts Payable 589.2 564 475.5 418.1 218.2
    Accrued Expenses 2073.9 1880.5 1502.3 1037.4 751.3
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 719.7
    Other Current Liabilities, Total 478.2 768.3 719.6 641.1 473.3
    Total Liabilities 6550.5 6666 6138 3715.5 2977.2
    Total Long Term Debt 2701.4 1980 2695.7 713.9 708.5
    Capital Lease Obligations 720 0 717.2 713.9 708.5
    Other Liabilities, Total 707.8 753.5 744.9 905 825.9
    Total Equity 22664 18768.8 11025.3 11089.7 8757.3
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.1 0.1 0.1 0.1 0.1
    Additional Paid-In Capital 9949.3 8087.5 6716.2 4428.6 3911.6
    Retained Earnings (Accumulated Deficit) 23306.7 18968.3 10893 7379.8 5254.3
    Treasury Stock - Common -10353.3 -8260.9 -6613.3 -739.9 -396.4
    Other Equity, Total -238.8 -26.2 29.3 21.1 -12.3
    Total Liabilities & Shareholders’ Equity 29214.5 25434.8 17163.3 14805.2 11734.5
    Total Common Shares Outstanding 109.6 108.675 106.951 110.277 109.006
    Long Term Debt 1981.4 1980 1978.5
    Intangibles, Net 915.5
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 18634.8 16923 16909.2 15884.1 15428.6
    Cash and Short Term Investments 9913.6 8927.7 8959.7 7742.3 7021.7
    Cash & Equivalents 2152.3 1937.2 3916.3 3105.9 3491.3
    Short Term Investments 7761.3 6990.5 5043.4 4636.4 3530.4
    Total Receivables, Net 5584.5 5121.3 5118.6 5328.7 5548.3
    Accounts Receivable - Trade, Net 5584.5 5121.3 5118.6 5328.7 5548.3
    Total Inventory 2562 2507.7 2424.7 2401.9 2412.2
    Prepaid Expenses 574.7 360.8 406.2 411.2 446.4
    Other Current Assets, Total 5.5
    Total Assets 32163.3 30657.5 30059.9 29214.5 27677.8
    Property/Plant/Equipment, Total - Net 4006.1 3922.6 3880.9 3763 3704.2
    Long Term Investments 5839.3 6405.5 6114.9 6640.1 6016.9
    Other Long Term Assets, Total 2665.9 2453.4 2226.2 2011.8 1724
    Total Current Liabilities 3598.6 3104.4 3100.1 3141.3 2879.2
    Accounts Payable 536.6 547.3 599.5 589.2 535.6
    Accrued Expenses 2644.7 2176 2074.3 2074.2 1796.4
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0
    Other Current Liabilities, Total 417.3 381.1 426.3 477.9 547.2
    Total Liabilities 7258.9 6639.6 6564.7 6550.5 6239
    Total Long Term Debt 2702.6 2702.2 2701.8 2701.4 2701.1
    Long Term Debt 1982.6 1982.2 1981.8 1981.4 1981.1
    Capital Lease Obligations 720 720 720 720 720
    Other Liabilities, Total 957.7 833 762.8 707.8 658.7
    Total Equity 24904.4 24017.9 23495.2 22664 21438.8
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.1018 0.1018 0.1018 0.1 0.1
    Additional Paid-In Capital 11251.5 10888.5 10597.7 9949.3 9518.2
    Retained Earnings (Accumulated Deficit) 26100.7 25092.9 24124.5 23306.7 22109.6
    Treasury Stock - Common -12271.1 -11765.9 -11045.5 -10353.3 -9914
    Other Equity, Total -176.802 -197.702 -181.602 -238.8 -275.1
    Total Liabilities & Shareholders’ Equity 32163.3 30657.5 30059.9 29214.5 27677.8
    Total Common Shares Outstanding 108.8 108.9 109.7 109.6 108.8
    Intangibles, Net 1017.2 953 928.7 915.5 804.1
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 4338.4 8075.3 3513.2 2115.8 2444.4
    Cash From Operating Activities 5014.9 7081.3 2618.1 2430 2195.1
    Cash From Operating Activities 341.4 286.2 235.9 210.3 148.2
    Deferred Taxes -746.4 -147.1 75.6 -130.6 -140
    Non-Cash Items 1324.8 783.4 297 435 439.5
    Cash Taxes Paid 1502.4 1218.4 188.1 342.3 205.6
    Cash Interest Paid 53.7 55.8 23.2 25 22.3
    Changes in Working Capital -243.3 -1916.5 -1503.6 -200.5 -697
    Cash From Investing Activities -3784.6 -5384.7 -70.6 -2027.8 -1463
    Capital Expenditures -1616.9 -551.9 -614.6 -429.6 -383.1
    Other Investing Cash Flow Items, Total -2167.7 -4832.8 544 -1598.2 -1079.9
    Cash From Financing Activities -1009 -1005.8 -1970.5 -252.1 -77.1
    Financing Cash Flow Items -445.7 -1032.7 -680.8 -188 -187.2
    Issuance (Retirement) of Stock, Net -563.3 26.9 -3271.6 -64.1 110.1
    Issuance (Retirement) of Debt, Net 0 0 1981.9 0
    Net Change in Cash 221.3 690.8 577 150.1 655
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 817.8 4338.4 3141.3 1825.6 973.5
    Cash From Operating Activities 1367.6 5014.9 3295 2666.1 2101.7
    Cash From Operating Activities 99.5 341.4 241.3 148.7 74.3
    Deferred Taxes -216.5 -746.4 -466.7 -381 -225
    Non-Cash Items 425.9 1324.8 1004.4 1030.9 455.7
    Changes in Working Capital 240.9 -243.3 -625.3 41.9 823.2
    Cash From Investing Activities -235.7 -3784.6 -1926.9 -2119.2 -1705.3
    Capital Expenditures -279.1 -1616.9 -1364.7 -295.4 -141.8
    Other Investing Cash Flow Items, Total 43.4 -2167.7 -562.2 -1823.8 -1563.5
    Cash From Financing Activities -322.5 -1009 -761.4 -36.4 64.7
    Financing Cash Flow Items -97 -445.7 -256.6 -147.7 -98.8
    Issuance (Retirement) of Stock, Net -225.5 -563.3 -504.8 111.3 163.5
    Net Change in Cash 809.4 221.3 606.7 510.5 461.1
    Issuance (Retirement) of Debt, Net 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Fidelity Management & Research Company LLC Investment Advisor 8.355 8918189 -212604 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.2533 8809572 8422 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.6404 6020629 -41844 2023-06-30 LOW
    Capital World Investors Investment Advisor 5.1999 5550382 -280204 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 4.727 5045619 136204 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.6757 4990870 97254 2023-06-30 LOW
    Capital International Investors Investment Advisor 2.7699 2956615 803143 2023-06-30 LOW
    Dodge & Cox Investment Advisor/Hedge Fund 2.2432 2394355 9654 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.1371 2281129 63136 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 1.9735 2106541 74167 2023-06-30 LOW
    Invesco Capital Management (QQQ Trust) Investment Advisor 1.7036 1818471 -10055 2023-09-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.5635 1668932 -98987 2023-06-30 LOW
    Loomis, Sayles & Company, L.P. Investment Advisor/Hedge Fund 1.1968 1277484 -34923 2023-06-30 LOW
    Yancopoulos (George D) Individual Investor 1.1452 1222370 -16824 2023-04-11
    Putnam Investment Management, L.L.C. Investment Advisor/Hedge Fund 1.0955 1169321 4004 2023-06-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9054 966467 84157 2022-12-31 LOW
    American Century Investment Management, Inc. Investment Advisor/Hedge Fund 0.8307 886668 -75042 2023-06-30 LOW
    Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7936 847129 -1998 2023-06-30 LOW
    BlackRock Asset Management Ireland Limited Investment Advisor 0.7587 809811 -9968 2023-06-30 LOW
    Neuberger Berman, LLC Investment Advisor/Hedge Fund 0.6639 708663 19784 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Regeneron Company profile

    Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
    Industry: Bio Therapeutic Drugs

    777 Old Saw Mill River Road
    TARRYTOWN
    NEW YORK 10591
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    Gold

    2,046.41 Price
    +0.480% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    15,956.60 Price
    +0.220% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Oil - Crude

    75.75 Price
    +0.130% 1D Chg, %
    Long position overnight fee -0.0165%
    Short position overnight fee -0.0054%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.62 Price
    +0.690% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading